Outlook Therapeutics

+$0.16 (+13.01%) Today
+$0.02 (+1.44%) As of 9:23 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell OTLK and other ETFs, options, and stocks.

About OTLK

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF.

CEO
C. Russell Trenary
Employees
9
Headquarters
Iselin, New Jersey
Founded
2010

OTLK Key Statistics

Market cap
311.72M
Price-Earnings ratio
—
Dividend yield
—
Average volume
1.55M
High today
$1.43
Low today
$1.22
Open price
$1.25
Volume
2.83M
52 Week high
$4.26
52 Week low
$0.9285

OTLK Earnings

-$0.12
-$0.08
-$0.04
$0.00
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Estimated
— per share
Actual
Expected Feb 14, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure